Ironwood Pharmaceuticals, a healthcare company based in Boston, Massachusetts, specializes in the development and marketing of gastrointestinal (GI) products. The company's flagship product, linaclotide, a guanylate cyclase type-C (GC-C) agonist for treating adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, is available in the United States, Mexico, Japan, and China under the LINZESS name and in Canada and European countries under the CONSTELLA name. Moreover, Ironwood Pharmaceuticals is working on several other products, including IW-3300, a GC-C agonist for treating visceral pain conditions, and CNP-104, an immune nanoparticle for tackling primary biliary cholangitis. Ironwood Pharmaceuticals has established strategic partnerships with big pharma players like AstraZeneca AB,AbbVie Inc. and Astellas Pharma Inc. to develop and commercialize linaclotide. The company, founded as Microbia, Inc. in 1998, later changed its name in April 2008 to Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals's ticker is IRWD
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 201-500 employees working at Ironwood Pharmaceuticals
It is ironwoodpharma.com
Ironwood Pharmaceuticals is in the Healthcare sector
Ironwood Pharmaceuticals is in the Drugs - Generic industry
The following five companies are Ironwood Pharmaceuticals's industry peers: